Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Depression With Quetiapine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects between the ages of 18 to 75 years.~* A Structured Clinical Interview for the DSM-IV (SCID) derived diagnosis of major depression with psychosis, single or recurrent episode (unipolar or bipolar).~* Subjects may have an anxiety disorder or an additional mood disorder such as dysthymia.~* Baseline 24-item Hamilton Depression Rating Scale (HDRS) score of greater than or equal to 21.~* A baseline Positive and Negative Syndrome Scale (PANSS) score of greater than or equal to 4 on at least one of the 4 psychosis items.~* Women of childbearing potential must agree to practice a medically accepted means of contraception.~* Length of current episode no longer than 3 months.~Exclusion Criteria:~* Pregnant or lactating women~* Women of child-bearing age who refuse a pregnancy test or who refuse to use a contraceptive technique when sexually active.~* Persons with other psychotic disorders; a mood disorder due to a general medical condition or substance-induced; substance dependence disorder in the last 6 months; substance abuse in the last 6 months or a dementing disorder are excluded.~* Persons with serious, unstable medical illnesses.~* Subjects who have been intolerant or nonresponsive to adequate trials of quetiapine, haloperidol and/or citalopram.~* Subjects who have received an injectable decanoate medication within 1 half life of the medication (i.e, 4 weeks for haloperidol or 2 weeks for fluphenazine).~* Subjects who have received fluoxetine within 4 weeks prior to randomization.~* Subjects who have received aripiprazole within 2 weeks prior to randomization.~* Subjects who have been treated with ECT within the last 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).